Tender detail
Non-exclusive rebate agreement for glycopyrronium + indacaterol under Section 130a(8) SGB V, 1 January 2027 to 31 December 2028
Summary
DAK-Gesundheit intends to conclude non-exclusive medicine rebate agreements with interested pharmaceutical companies for medicines containing the active ingredients glycopyrronium and indacaterol (ATC R03AL12). The agreement is intended to run from 1 January 2027 to 31 December 2028, but will end automatically if an exclusive agreement takes effect earlier.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.